Actuate Therapeutics, Inc. (NasdaqGM: ACTU)
Health Care · Biotechnology · US
$1.49
+47.52% today · -87.8% 1Y
Actuate Therapeutics, Inc. (NasdaqGM: ACTU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $24.17M and employs 12 people.
Over the last twelve months the share price has lost 87.8%, trading between 1.02 and 9.22.
Tweenvest scores Actuate Therapeutics, Inc. across four factors: quality 25/100. Its strongest factor is quality.
ACTU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $24.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.98
- Dividend yield
- —
- Beta (5Y)
- 0.78
- 52-week high
- $9.22
- 52-week low
- $1.02
- Avg volume (3M)
- —
- Shares outstanding
- 23.93M
- Employees
- 12
- Next earnings
- —
About Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
- ISIN
- US0050831009
- Founded
- 2015
- Listed since
- Aug 13, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.76 | +0.47% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.16 | -0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.72 | +1.35% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.13 | +1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.58 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.86 | +14.38% |
Figures last refreshed Aug 18, 2026.